{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenosine&page=7", "query": { "condition": "Adenosine", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 152, "total_pages": 16, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenosine&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenosine&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-04T21:28:07.795Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00208312", "title": "ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Coronary Artery Disease" ], "interventions": [ { "name": "Regadenoson", "type": "DRUG" }, { "name": "Adenosine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 787, "start_date": "2004-04", "completion_date": "2005-06", "has_results": false, "last_update_posted_date": "2009-11-26", "last_synced_at": "2026-11-04T21:28:07.795Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00208312" }, { "nct_id": "NCT05024097", "title": "A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rectal Cancer" ], "interventions": [ { "name": "Etrumadenant (AB928)", "type": "DRUG" }, { "name": "Radiation therapy", "type": "RADIATION" }, { "name": "FOLFOX regimen", "type": "DRUG" }, { "name": "Zimberelimab (AB122)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 43, "start_date": "2022-03-31", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-11-04T21:28:07.795Z", "location_count": 3, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05024097" }, { "nct_id": "NCT06119217", "title": "Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "TTX-030, nab-paclitaxel and gemcitabine", "type": "COMBINATION_PRODUCT" }, { "name": "TTX-030, budigalimab, nab-paclitaxel and gemcitabine", "type": "COMBINATION_PRODUCT" }, { "name": "Nab-Paclitaxel and gemcitabine", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Trishula Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 194, "start_date": "2024-03-25", "completion_date": "2026-03-06", "has_results": true, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-11-04T21:28:07.795Z", "location_count": 28, "location_summary": "Tucson, Arizona • Hot Springs, Arkansas • Bakersfield, California + 25 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06119217" }, { "nct_id": "NCT00833963", "title": "A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Pregnancy" ], "interventions": [ { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Ado-Trastuzumab Emtansine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 20, "start_date": "2009-01-14", "completion_date": "2017-04-13", "has_results": false, "last_update_posted_date": "2019-05-16", "last_synced_at": "2026-11-04T21:28:07.795Z", "location_count": 1, "location_summary": "Wilmington, North Carolina", "locations": [ { "city": "Wilmington", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00833963" }, { "nct_id": "NCT05408845", "title": "Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Salivary Gland Carcinoma", "Recurrent Salivary Gland Carcinoma", "Stage III Major Salivary Gland Cancer AJCC v8", "Stage IV Major Salivary Gland Cancer AJCC v8", "Unresectable Salivary Gland Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab Deruxtecan", "type": "BIOLOGICAL" }, { "name": "Trastuzumab Emtansine", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 146, "start_date": "2023-03-03", "completion_date": "2033-07-31", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-11-04T21:28:07.795Z", "location_count": 154, "location_summary": "Birmingham, Alabama • Duarte, California • Dublin, California + 127 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Dublin", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05408845" }, { "nct_id": "NCT00714103", "title": "8-Chloro-Adenosine in Chronic Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "8-Chloro-Adenosine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2008-06", "completion_date": "2016-10", "has_results": false, "last_update_posted_date": "2016-10-13", "last_synced_at": "2026-11-04T21:28:07.795Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00714103" }, { "nct_id": "NCT00298636", "title": "Dose-Response of Adenosine for Perioperative Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Perioperative Pain" ], "interventions": [ { "name": "adenosine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Xsira Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "18 Years to 65 Years · Female only" }, "enrollment_count": 160, "start_date": "2005-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2006-08-02", "last_synced_at": "2026-11-04T21:28:07.795Z", "location_count": 8, "location_summary": "San Francisco, California • Miami, Florida • Augusta, Georgia + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00298636" }, { "nct_id": "NCT05100589", "title": "Effect of PeakATP on Mood, Reaction Time and Cognition", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cognitive Change", "Mood" ], "interventions": [ { "name": "PeakATP", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "University of Central Florida", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 35, "start_date": "2021-10-06", "completion_date": "2022-04-19", "has_results": false, "last_update_posted_date": "2022-08-08", "last_synced_at": "2026-11-04T21:28:07.795Z", "location_count": 1, "location_summary": "Orlando, Florida", "locations": [ { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05100589" }, { "nct_id": "NCT00133042", "title": "The Effect of Omalizumab on Airway Responsiveness to Adenosine in Patients With Poorly Controlled Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "omalizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "26 Years", "sex": "ALL", "summary": "6 Years to 26 Years" }, "enrollment_count": 16, "start_date": "2004-12", "completion_date": "2006-12", "has_results": false, "last_update_posted_date": "2011-09-20", "last_synced_at": "2026-11-04T21:28:07.795Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00133042" }, { "nct_id": "NCT00380198", "title": "A Comparison Study of Apadenoson and Adenosine to Treadmill Exercise Stress.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Coronary Artery Disease" ], "interventions": [ { "name": "Apadenoson", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forest Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1500, "start_date": "2006-07", "completion_date": "2006-11", "has_results": false, "last_update_posted_date": "2017-02-01", "last_synced_at": "2026-11-04T21:28:07.795Z", "location_count": 42, "location_summary": "Huntsville, Alabama • Santa Rosa, California • Bridgeport, Connecticut + 38 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Bridgeport", "state": "Connecticut" }, { "city": "Guilford", "state": "Connecticut" }, { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT00380198" } ] }